FoundationOneLiquid CDx: FDA status

Approved Approved Jul 1, 2024. Indication: BRCA positive metastatic castration resistant prostate cancer, companion diagnostic for niraparib and abiraterone acetate Akeega. Company: Foundation Medicine.

Regulatory history

• Jul 1, 2024: Approved. FDA approved FoundationOneLiquid CDx as a companion diagnostic for Akeega niraparib and abiraterone acetate in BRCA positive metastatic castration resistant prostate cancer. foundationmedicine.com

All products in the FDA Tracker